BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 34906479)

  • 1. Risks of breast and ovarian cancer for women harboring pathogenic missense variants in BRCA1 and BRCA2 compared with those harboring protein truncating variants.
    Li H; Engel C; de la Hoya M; Peterlongo P; Yannoukakos D; Livraghi L; Radice P; Thomassen M; Hansen TVO; Gerdes AM; Nielsen HR; Caputo SM; Zambelli A; Borg A; Solano A; Thomas A; Parsons MT; Antoniou AC; Leslie G; Yang X; Chenevix-Trench G; Caldes T; Kwong A; Pedersen IS; Lautrup CK; John EM; Terry MB; Hopper JL; Southey MC; Andrulis IL; Tischkowitz M; Janavicius R; Boonen SE; Kroeldrup L; Varesco L; Hamann U; Vega A; Palmero EI; Garber J; Montagna M; Van Asperen CJ; Foretova L; Greene MH; Selkirk T; Moller P; Toland AE; Domchek SM; James PA; Thorne H; Eccles DM; Nielsen SM; Manoukian S; Pasini B; Caligo MA; Lazaro C; Kirk J; Wappenschmidt B; Spurdle AB; Couch FJ; Schmutzler R; Goldgar DE; ;
    Genet Med; 2022 Jan; 24(1):119-129. PubMed ID: 34906479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BRCA1 and BRCA2 unclassified variants and missense polymorphisms in Algerian breast/ovarian cancer families.
    Cherbal F; Salhi N; Bakour R; Adane S; Boualga K; Maillet P
    Dis Markers; 2012; 32(6):343-53. PubMed ID: 22684231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic testing in Poland and Ukraine: should comprehensive germline testing of
    Nguyen-Dumont T; Karpinski P; Sasiadek MM; Akopyan H; Steen JA; Theys D; Hammet F; Tsimiklis H; Park DJ; Pope BJ; Slezak R; Stembalska A; Pesz K; Kitsera N; Siekierzynska A; Southey MC; Myszka A
    Genet Res (Camb); 2020 Aug; 102():e6. PubMed ID: 32772980
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of specific and recurrent/founder pathogenic variants in BRCA genes in breast and ovarian cancer in North Africa.
    ElBiad O; Laraqui A; El Boukhrissi F; Mounjid C; Lamsisi M; Bajjou T; Elannaz H; Lahlou AI; Kouach J; Benchekroune K; Oukabli M; Chahdi H; Ennaji MM; Tanz R; Sbitti Y; Ichou M; Ennibi K; Badaoui B; Sekhsokh Y
    BMC Cancer; 2022 Feb; 22(1):208. PubMed ID: 35216584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of Late-Onset Breast Cancer in Genetically Predisposed Women.
    Boddicker NJ; Hu C; Weitzel JN; Kraft P; Nathanson KL; Goldgar DE; Na J; Huang H; Gnanaolivu RD; Larson N; Yussuf A; Yao S; Vachon CM; Trentham-Dietz A; Teras L; Taylor JA; Scott CE; Sandler DP; Pesaran T; Patel AV; Palmer JR; Ong IM; Olson JE; O'Brien K; Neuhausen S; Martinez E; Ma H; Lindstrom S; Le Marchand L; Kooperberg C; Karam R; Hunter DJ; Hodge JM; Haiman C; Gaudet MM; Gao C; LaDuca H; Lacey JV; Dolinsky JS; Chao E; Carter BD; Burnside ES; Bertrand KA; Bernstein L; Auer PW; Ambrosone C; Yadav S; Hart SN; Polley EC; Domchek SM; Couch FJ
    J Clin Oncol; 2021 Nov; 39(31):3430-3440. PubMed ID: 34292776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of the pathogenic variants of BRCA1 and BRCA2 using next-generation sequencing in women with familial breast cancer: a case-control study.
    Zayas-Villanueva OA; Campos-Acevedo LD; Lugo-Trampe JJ; Hernández-Barajas D; González-Guerrero JF; Noriega-Iriondo MF; Ramírez-Sánchez IA; Martínez-de-Villarreal LE
    BMC Cancer; 2019 Jul; 19(1):722. PubMed ID: 31331294
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel germline mutations in the BRCA1 and BRCA2 genes in Indian breast and breast-ovarian cancer families.
    Valarmathi MT; Sawhney M; Deo SSV; Shukla NK; Das SN
    Hum Mutat; 2004 Feb; 23(2):205. PubMed ID: 14722926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extended genetic analysis and tumor characteristics in over 4600 women with suspected hereditary breast and ovarian cancer.
    Öfverholm A; Törngren T; Rosén A; Arver B; Einbeigi Z; Haraldsson K; Ståhlbom AK; Kuchinskaya E; Lindblom A; Melin B; Paulsson-Karlsson Y; Stenmark-Askmalm M; Tham E; von Wachenfeldt A; Kvist A; Borg Å; Ehrencrona H
    BMC Cancer; 2023 Aug; 23(1):738. PubMed ID: 37563628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel BRCA1 and BRCA2 germline mutations and assessment of mutation spectrum and prevalence in Italian breast and/or ovarian cancer families.
    Giannini G; Capalbo C; Ristori E; Ricevuto E; Sidoni T; Buffone A; Cortesi E; Marchetti P; Scambia G; Tomao S; Rinaldi C; Zani M; Ferraro S; Frati L; Screpanti I; Gulino A
    Breast Cancer Res Treat; 2006 Nov; 100(1):83-91. PubMed ID: 16847550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A spectrum of BRCA1 and BRCA2 germline deleterious variants in ovarian cancer in Russia.
    Kechin A; Boyarskikh U; Barinov A; Tanas A; Kazakova S; Zhevlova A; Khrapov E; Subbotin S; Mishukova O; Kekeeva T; Demidova I; Filipenko M
    Breast Cancer Res Treat; 2023 Jan; 197(2):387-395. PubMed ID: 36367610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer Risks Associated With
    Li S; Silvestri V; Leslie G; Rebbeck TR; Neuhausen SL; Hopper JL; Nielsen HR; Lee A; Yang X; McGuffog L; Parsons MT; Andrulis IL; Arnold N; Belotti M; Borg Å; Buecher B; Buys SS; Caputo SM; Chung WK; Colas C; Colonna SV; Cook J; Daly MB; de la Hoya M; de Pauw A; Delhomelle H; Eason J; Engel C; Evans DG; Faust U; Fehm TN; Fostira F; Fountzilas G; Frone M; Garcia-Barberan V; Garre P; Gauthier-Villars M; Gehrig A; Glendon G; Goldgar DE; Golmard L; Greene MH; Hahnen E; Hamann U; Hanson H; Hassan T; Hentschel J; Horvath J; Izatt L; Janavicius R; Jiao Y; John EM; Karlan BY; Kim SW; Konstantopoulou I; Kwong A; Laugé A; Lee JW; Lesueur F; Mebirouk N; Meindl A; Mouret-Fourme E; Musgrave H; Ngeow Yuen Yie J; Niederacher D; Park SK; Pedersen IS; Ramser J; Ramus SJ; Rantala J; Rashid MU; Reichl F; Ritter J; Rump A; Santamariña M; Saule C; Schmidt G; Schmutzler RK; Senter L; Shariff S; Singer CF; Southey MC; Stoppa-Lyonnet D; Sutter C; Tan Y; Teo SH; Terry MB; Thomassen M; Tischkowitz M; Toland AE; Torres D; Vega A; Wagner SA; Wang-Gohrke S; Wappenschmidt B; Weber BHF; Yannoukakos D; Spurdle AB; Easton DF; Chenevix-Trench G; Ottini L; Antoniou AC
    J Clin Oncol; 2022 May; 40(14):1529-1541. PubMed ID: 35077220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of BRCA1 and BRCA2 pathogenic variants in 8627 unselected patients with breast cancer: stratification of age at diagnosis, family history and molecular subtype.
    Zang F; Ding X; Chen J; Hu L; Sun J; Zhang J; Xu Y; Yao L; Xie Y
    Breast Cancer Res Treat; 2022 Oct; 195(3):431-439. PubMed ID: 35974241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frequency of mutations in BRCA genes and other candidate genes in high-risk probands or probands with breast or ovarian cancer in the Czech Republic.
    Riedlova P; Janoutova J; Hermanova B
    Mol Biol Rep; 2020 Apr; 47(4):2763-2769. PubMed ID: 32180084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Twenty-three novel BRCA1 and BRCA2 sequence alterations in breast and/or ovarian cancer families in Southern Germany.
    Meyer P; Voigtlaender T; Bartram CR; Klaes R
    Hum Mutat; 2003 Sep; 22(3):259. PubMed ID: 12938098
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High prevalence of deleterious BRCA1 and BRCA2 germline mutations in arab breast and ovarian cancer patients.
    Alhuqail AJ; Alzahrani A; Almubarak H; Al-Qadheeb S; Alghofaili L; Almoghrabi N; Alhussaini H; Park BH; Colak D; Karakas B
    Breast Cancer Res Treat; 2018 Apr; 168(3):695-702. PubMed ID: 29297111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of pathogenic variants in BRCA1 and BRCA2 genes using next-generation sequencing in women with triple negative breast cancer from South India.
    Rajagopal T; Seshachalam A; Jothi A; Rathnam KK; Talluri S; Venkatabalasubranian S; Dunna NR
    Mol Biol Rep; 2022 Apr; 49(4):3025-3032. PubMed ID: 35020120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Germline variants profiling of BRCA1 and BRCA2 in Chinese Hakka breast and ovarian cancer patients.
    Zhang Y; Wu H; Yu Z; Li L; Zhang J; Liang X; Huang Q
    BMC Cancer; 2022 Aug; 22(1):842. PubMed ID: 35918668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of BRCA1/BRCA2 founder variants by haplotype analysis.
    Kwon WK; Jang HJ; Lee JE; Park YH; Ryu JM; Yu J; Jang JH; Kim JW
    Cancer Genet; 2022 Aug; 266-267():19-27. PubMed ID: 35671604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of BRCA1 and BRCA2 pathogenic and likely pathogenic variants in non-selected ovarian carcinoma patients in Brazil.
    Cotrim DP; Ribeiro ARG; Paixão D; de Queiroz Soares DC; Jbili R; Pandolfi NC; Cezana C; de Cássia Mauro C; Mantoan H; Bovolim G; de Brot L; Torrezan GT; Carraro DM; Baiocchi G; da Cruz Formiga MN; da Costa AABA
    BMC Cancer; 2019 Jan; 19(1):4. PubMed ID: 30606148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of Risk-Reducing Salpingo-Oophorectomy With Breast Cancer Risk in Women With BRCA1 and BRCA2 Pathogenic Variants.
    Choi YH; Terry MB; Daly MB; MacInnis RJ; Hopper JL; Colonna S; Buys SS; Andrulis IL; John EM; Kurian AW; Briollais L
    JAMA Oncol; 2021 Apr; 7(4):585-592. PubMed ID: 33630024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.